Bernstein raised the firm’s price target on Regeneron (REGN) to $818 from $781 and keeps an Outperform rating on the shares. The firm notes the company appears to have finally found its footing, with good commercial execution on Eylea and Dupixent, combined with an encouraging Eylea HD regulatory update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target raised to $865 from $815 at Guggenheim
- Regeneron price target raised to $627 from $543 at BofA
- Cautious Outlook on Regeneron Amid Eylea Erosion and Medicare Policy Risks
- Regeneron Pharmaceuticals Faces Financial Risks Amid Tariff and Trade Challenges
- Regeneron Pharmaceuticals Reports Q3 2025 Financial Results